Next-Generation Nanobody Therapeutics Targeting SARS-CoV-2 E2 Glycoprotein and Surface Glycoprotein for COVID-19 Intervention

VHH-P431 is a humanized single-domain nanobody engineered to target the E2 glycoprotein precursor surface glycoprotein, the essential antigenic determinant of human SARS-CoV-2 and SARS-CoV. Developed through expression in human embryonic kidney 293F cells, this advanced antibody construct is currently in the Biological Testing phase. VHH-P431 offers a novel therapeutic approach for the treatment of SARS-CoV-2 infection (COVID-19) by specifically engaging the E2 glycoprotein precursor surface glycoprotein, a critical mediator of viral entry and pathogenesis. Its unique molecular properties highlight significant potential to address unmet needs in antiviral therapy.

Licensing Opportunity

VHH-P431 is available for out-licensing and strategic partnership opportunities. Interested parties are encouraged to contact us to explore collaboration in the further development and commercialization of this innovative nanobody-based therapeutic.

Development Phase

Modality

VHH-P431 is an alpaca-derived, single-domain antibody, also known as a nanobody, fused to a human Fc domain via a flexible 4GS peptide linker, and expressed in human HEK293F cells. This modular structure confers several key therapeutic advantages, including small molecular size for improved tissue penetration and rapid distribution, exceptional thermal and chemical stability, and the potential for robust manufacturing scalability. The human Fc fusion extends half-life and enables engagement of immune effector functions. These combined features make VHH-P431 a promising solution for the treatment of SARS-CoV-2 infection, potentially overcoming barriers associated with conventional antibody therapeutics.

Target

The E2 glycoprotein precursor Surface glycoprotein is a transmembrane, trimeric protein crucial for the entry of coronaviruses, including SARS-CoV-2, into host cells. Highly expressed on the viral envelope, the E2 glycoprotein precursor Surface glycoprotein mediates attachment to cell surface receptors and subsequent membrane fusion, initiating infection. As the primary antigenic target, the E2 glycoprotein precursor Surface glycoprotein is a scientifically validated molecule for intervention strategies against SARS-CoV-2 infection. Its surface accessibility and vital functional role render the E2 glycoprotein precursor Surface glycoprotein an ideal target for neutralization by therapeutic antibodies. VHH-P431’s precise targeting of the E2 glycoprotein precursor Surface glycoprotein positions it as a strategically attractive asset in the ongoing effort to develop first-in-class anti-viral biologics.

Mechanism of Action

VHH-P431 exerts its therapeutic effect by selectively binding to the E2 glycoprotein precursor Surface glycoprotein, an essential structural protein mediating viral attachment and fusion with host cells. This interaction is designed to disrupt the binding of the virus to host cell surface receptors, thus inhibiting viral entry and subsequent replication. By blocking the function of the E2 glycoprotein precursor Surface glycoprotein, VHH-P431 aims to neutralize viral infectivity and impede the progression of SARS-CoV-2 infection. As a nanobody platform, VHH-P431 presents opportunities for advanced therapeutic applications, including fusion to cytotoxic payloads (such as in antibody-drug conjugates) or engineering into multi-specific formats to broaden antiviral coverage and functional versatility.

SARS-CoV-2 Infection (COVID-19)

SARS-CoV-2 infection (COVID-19) is an acute respiratory disease caused by the novel coronavirus SARS-CoV-2, which has resulted in a global pandemic with profound health and socioeconomic consequences. Characterized by human-to-human transmission, variable clinical presentations, and potential for severe or fatal outcomes—particularly among vulnerable populations—SARS-CoV-2 infection continues to impose a heavy burden on healthcare systems worldwide. Current treatment paradigms consist primarily of antiviral agents, immune modulators, and supportive care, yet their efficacy is limited by issues such as emerging variants, resistance, and variable patient response. There remains a pressing need for innovative therapies that can directly and effectively neutralize viral infectivity and adapt to viral evolution. VHH-P431, with its specific engagement of the E2 glycoprotein precursor surface glycoprotein and advanced nanobody design, represents a significant opportunity to redefine the standards of care in COVID-19 management, addressing critical gaps in antiviral prophylaxis and treatment.